Special Investigation For Renal Cell Carcinoma (RCC) Of Sutent (Regulatory Post Marketing Commitment Plan)
Phase 4
N/A
N/A
N/A
N/A
Open (Enrolling by invite only)
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
Special Investigation For Renal Cell Carcinoma (RCC) Of Sutent (Regulatory Post Marketing Commitment Plan)
All the patients whom an investigator prescribes the first sunitinib malate(Sutent) should
be registered.
Inclusion Criteria:
- Patients need to be administered sunitinib malate (Sutent) in order to be enrolled in
the surveillance.
Exclusion Criteria:
- Patients not administered sunitinib malate (Sutent).
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Adverse drug reaction not expected from the LPD (unknown adverse drug reaction).
Outcome Time Frame:
24 weeks
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
A6181176
NCT ID:
NCT00716625
Start Date:
June 2008
Completion Date:
April 2014
Related Keywords:
- Carcinoma, Renal Cell
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
